Program
CU06-1004
Also written as “CU06-1004, Single dose” and “CU06-1004, Multiple doses”.
Its studies are mostly in Macular Edema, led by Curacle.
Furthest: phase 2, since Sep 25, 20223 company-led studies, 1 open or runningNext primary completion: Jan 1, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Curacle | 31 open or running | phase 2since Sep 25, 2022 | Mar 5, 2021 | Jan 1, 2028phase 2 · NCT07459829 |
Also a collaborator on its studies: kcrn-research-llc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 5, 2021First study: phase 1 study in Diabetic Macular EdemaFirst studyNCT04795037 · 81 enrolled · United States
- Sep 25, 2022Phase 2 study in Diabetic Macular EdemaNCT05573100 · 67 enrolled · United States, Puerto Rico
- Feb 26, 2026Phase 2 study in DMENCT07459829 · 156 planned
Ahead
- Jan 1, 2028Primary completion: phase 2 study in DMENCT07459829
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07459829DME | 2 | Not yet recruiting | Jan 1, 2028 | 156 |
| NCT05573100Diabetic Macular Edema · United States, Puerto Rico | 2 | Completed | May 31, 2023 | 67 |
| NCT04795037Diabetic Macular Edema · United States | 1 | Completed | Mar 2, 2022 | 81 |
How it is read
Names in the registry
- “CU06-1004”, 2 entries
- “CU06-1004, Single dose”, 1 entry
- “CU06-1004, Multiple doses”, 1 entry
Conditions, from the studies’ own filings
- Macular Edema, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.